Sixth Element Capital

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing treatments for patients suffering from hormone-resistant breast and prostate cancer, addressing significant unmet clinical needs in this area. Azeria specializes in a pipeline of small molecules that selectively inhibit pioneer factors, which are crucial in the development and progression of these cancers. By targeting these factors, the company aims to provide more effective treatment options for healthcare professionals managing various cancer types, thereby improving outcomes for patients.

Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing treatments for patients suffering from hormone-resistant breast and prostate cancer, addressing significant unmet clinical needs in this area. Azeria specializes in a pipeline of small molecules that selectively inhibit pioneer factors, which are crucial in the development and progression of these cancers. By targeting these factors, the company aims to provide more effective treatment options for healthcare professionals managing various cancer types, thereby improving outcomes for patients.

AdoRx Therapeutics Limited is a drug discovery company based in Edinburgh, United Kingdom, focused on developing new therapeutics for cancer by modulating the adenosine pathway. Founded in 2017, the company targets the high levels of adenosine present in the tumor microenvironment, which allow cancer cells to evade the immune system. AdoRx's lead programs concentrate on creating tailored adenosine receptor antagonists designed to counteract the effects of elevated adenosine levels. The leadership team at AdoRx has extensive experience in drug discovery, having previously developed over 25 clinical candidates. The company is supported by investment from Epidarex Capital and Sixth Element Capital, enhancing its capacity to advance innovative cancer treatments.

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The company’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.